Last Updated on August 23, 2021 by The Health Master
Here are some facts about Zydus Cadila’s Vaccine ZyCoV-D
A day after getting the emergency use authorisation (EUA) in India, country’s leading multinational pharmaceutical company Zydus Cadila has said that the commercial rollout of its ZyCoV-D vaccine will start from mid-September. The pharma major informed about the future rollout plan in a virtual press conference held on Saturday.
Zydus‘ Managing Director Sharvil Patel, said that the company is aiming at increasing the production of the vaccine up to 1 crore doses per month from the month of October with the help of the new production plant and hopefully supply 4 crore doses of ZyCoV-D by end of December.
Talking about the vaccine price, he said that there will be more clarity about the price of the vaccine by next week.
“So far, 28,000 volunteers have participated in the trial of the vaccine at more than 50 locations. The results of the first and second trials have been published in the Lancet for scientific research and scrutiny, the results of the third phase trial will take 2 to 3 months to come,” said Patel.
The pharma company chief further said that so far, all the volunteers above the age of 12 years have participated in the trial, while 1,400 children whose age is less than 12 years have applied for the trial. “No adverse impacts were observed during the vaccine trials, we have also conducted trials on Delta and Delta Plus variants,” he said.
Here Are Some Facts About The Zydus Cadila Vaccine
- As per the company’s announcement, ZyCoV-D vaccine has shown 66 per cent effective against the delta variant, with higher antibody levels in the age group of 12 years and 18 years.
- Zydus vaccine is the world’s first vaccine to be delivered with a microneedle injector manufactured with DNA technology that can reduce injection costs and adverse effects by 25 per cent.
- The vaccine is stored at 2-8 degrees Celsius and has shown good stability at 25-degrees C for at least three months
- Zydus Cadila‘s vaccine is a three-dose indigenous Covid-19 vaccine can be administered to people aged 12 and above
- It will be given at an interval of 0-28-56-days using The PharmaJet — a needle-free applicator for painless intradermal vaccine delivery.
- It becomes the sixth vaccine to get approval for use in India